← Back to guidelines
Pediatrics7 papers

Kasabach-Merritt syndrome

Last edited: 4/15/2026

Overview

Kasabach-Merritt syndrome (KMS) is characterized by severe thrombocytopenia associated with large, locally infiltrative hemangiomas, often leading to life-threatening bleeding and coagulopathy 13.

Diagnosis

  • Clinical Presentation: Severe thrombocytopenia, large hemangiomas, and signs of coagulopathy 13.
  • Histopathology: Predominant vascular lesions include tufted angiomas (TA) and Kaposiform hemangioendotheliomas (KHE), with infantile hemangiomas less common 2.
  • Laboratory Tests: Platelet count monitoring, coagulation profile 13.
  • Management

  • First-Line Treatments:
  • - Corticosteroids: Initial treatment with variable response rates (11.4% response in one study) 3. - Interferon-Alpha: Effective in cases resistant to other therapies, leading to significant platelet count increase and hemangioma reduction 4.
  • Adjunctive Treatments:
  • - Radiation Therapy: Critical in refractory cases, showing improvement in platelet counts and resolution of hemangiomas 1. - Combined Therapy: Steroids combined with radiation therapy often used when initial treatments fail 3.

    Special Populations

  • Pediatrics: Majority of cases diagnosed in infancy with superficial skin hemangiomas; multimodal approaches are essential 3.
  • Comorbidities: Severe thrombocytopenia and hemangioma extension may preclude surgical intervention, necessitating alternative therapies like interferon 4.
  • Key Recommendations

  • Initiate corticosteroids as first-line therapy for Kasabach-Merritt syndrome, though response rates may be limited 3 (Evidence: Moderate).
  • Consider combined corticosteroid and radiation therapy for patients who do not respond adequately to corticosteroids alone 3 (Evidence: Moderate).
  • Evaluate interferon-alpha therapy for severe, refractory cases where other treatments fail, given its potential for significant clinical improvement 4 (Evidence: Weak).
  • References

    1 Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. Journal of medical imaging and radiation oncology 2009. link 2 Alvarez-Mendoza A, Lourdes TS, Ridaura-Sanz C, Ruiz-Maldonado R. Histopathology of vascular lesions found in Kasabach-Merritt syndrome: review based on 13 cases. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2000. link 3 Shin HY, Ryu KH, Ahn HS. Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome. Pediatrics international : official journal of the Japan Pediatric Society 2000. link 4 Nako Y, Fukushima N, Igarashi T, Hoshino M, Sugiyama M, Tomomasa T et al.. Successful interferon therapy in a neonate with life-threatening Kasabach-Merritt syndrome. Journal of perinatology : official journal of the California Perinatal Association 1997. link

    Original source

    1. [1]
      Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome.Leong E, Bydder S Journal of medical imaging and radiation oncology (2009)
    2. [2]
      Histopathology of vascular lesions found in Kasabach-Merritt syndrome: review based on 13 cases.Alvarez-Mendoza A, Lourdes TS, Ridaura-Sanz C, Ruiz-Maldonado R Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society (2000)
    3. [3]
      Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome.Shin HY, Ryu KH, Ahn HS Pediatrics international : official journal of the Japan Pediatric Society (2000)
    4. [4]
      Successful interferon therapy in a neonate with life-threatening Kasabach-Merritt syndrome.Nako Y, Fukushima N, Igarashi T, Hoshino M, Sugiyama M, Tomomasa T et al. Journal of perinatology : official journal of the California Perinatal Association (1997)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG